Figure 1 from Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study
Year: 2026
Type: other
Abstract: Survival outcome. Kaplan–Meier plot of (A) time to PFS per RECIST 1.1 and (B) OS.
Authors: Marc Pelletier, Jie Yang, Mukta Joshi, Angelo Grauel, Cara Abecunas, Maria Athina Altzerinakou, Zheng Zhou, Xiaoping Zhu, Kirk Clark, Li Li, Li-Yuan Bai, Michele Milella, Teresa Macarulla Mercade, Wai Meng David Tai, Bruno Bockorny, Peter Grell, Shivan Sivakumar, Mark Ka Wong, Cheng Ean Chee, Thomas Aparicio, Gerald Prager, Geraldine Bostel, Brigitte Schiessl, Heiko Maacke, Glenn Dranoff, Alice Shaw, Claire Fabre, Jennifer Mataraza, Shiva Malek, Viviana Cremasco
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7213249697